Semaglutide

07.05.2025

Semaglutide

Why in the news?   

The recent New England Journal of Medicine study published that a weekly dose of semaglutide has shown remarkable results in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH).

What is Semaglutide?

• Semaglutide is a GLP-1 receptor agonist, originally developed for Type 2 diabetes
• It is the active ingredient in drugs like Ozempic (for diabetes) and Wegovy (for weight loss).

What is MASH?

• MASH (Metabolic Dysfunction-Associated Steatohepatitis) is a serious form of fatty liver disease marked by excessive fat accumulation, inflammation, and fibrosis in the liver.
• It occurs independently of alcohol use and is often linked to overnutrition, obesity, diabetes, and metabolic syndrome.
• It is considered a progressive liver condition and can lead to cirrhosis or liver failure if untreated.

Why is this study important?

• There is currently no approved drug treatment for MASH, making this finding highly significant.
• The results show that semaglutide not only improves liver histology but also addresses the root metabolic dysfunctions, such as insulin resistance and inflammation.
• It provides hope for an additional therapeutic option for patients already vulnerable to cardiovascular, metabolic and renal complications—areas where semaglutide has proven benefits.

                               Source: Indian Express

Consider the following statements with reference to the MASH (Metabolic Dysfunction-Associated Steatohepatitis):

1. It is a serious form of fatty liver disease marked by excessive fat accumulation, inflammation and fibrosis in the liver.

2. It occurs independently of alcohol use and is often linked to overnutrition, obesity, diabetes and metabolic syndrome.

Which of the statements given above is/are correct?

A.1 only

B.2 only

C.Both 1 and 2

D.Neither 1 nor 2

Answer C